Gh Research Plc GHRS

$20.02 -1.09 (-5.16%)

Valuation

Market cap
1,448,336,000
Revenue TTM
$0
Net income TTM
$-48,260,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
229,600
Avg volume
287,564
Day's range
$20.01 – $21.23
Shares out
68,609,000
Stochastic %K
24%
Beta
1.32
Analysts
Strong Sell
Price target
$42.89

Price

Company profile

GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpar...

Show more

GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression. It also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.

Industry
Biotechnology
Sector
Healthcare
Phone
353 1 437 8334
Website
https://www.ghres.com
Address
Joshua Dawson House, Dawson Street, Dublin, Ireland

Latest news

Stocktwits

jebes Oct 12, 8:15 PM
$GHRS so is someone driving this down on purpose? It seems that way. Every day it drops by 3 or 4% for no apparent reason
0 replies
leLu83 Oct 9, 1:59 PM
$GHRS 5 year cup and handle ready for blast off 🚀 Clean cap structure. 11 min duration molecule. No therapist required. JJ and Abbvie target. EV 1.1B when atai was BO for 3.8B. 360M in cash no debt. Held by insiders and tutes. Low float. 68M OS. Will move in Q4 for P3 initiation. Will test all time highs and then BO in early 2027 for $45-$50 plus CVRs. 💰 🤑
0 replies
putINwork Oct 9, 3:13 AM
$GHRS $HELP my understanding is that this is an inhalation med. That’s very hard with anyone with bronchospasm, so many more things to go wrong. Check out Loxapine Inhaled - was a disaster
1 replies
summerof08 Oct 9, 12:54 AM
$HELP interesting tidbit I saw earlier today on linkedin Halstead has a link to J&J through insta-cellular Here’s a link into $GHRS The spravato clinics run on thin margins, so the shorter administration time on gh001 would be beneficial Don’t love the non-completion on gh001 though This data will be interesting, anyone else seen this & have thoughts?
1 replies
jebes Oct 6, 12:40 PM
$GHRS lol 400 shares dropped the price by 2$ 😅😅
0 replies
leLu83 Oct 5, 7:58 PM
$GHRS took some 💪
0 replies
directorwalsh Oct 2, 7:57 PM
$GHRS started position here. Still a ways to go but elite data + interesting pipeline. ~$1B EV with ample cash is too low here. Better version of $ATAI compound Lilly is paying $3B+ for.
0 replies
leLu83 Oct 2, 2:52 PM
$GHRS only acquisition target left $ATAI
0 replies